FibroBiologics Clears First cGMP Batch Release for Fibroblast DFU Trial

FibroBiologics has released its first cGMP-manufactured batch of CYWC628, clearing the quality and safety testing requirements necessary to initiate patient enrollment in a Phase 1/2 clinical trial targeting diabetic foot ulcers. For QA directors and manufacturing leads tracking advanced therapy medicinal products, the milestone marks one of the earliest fibroblast-based cell therapies to clear a full cGMP batch release for clinical use in this indication, underscoring the sector-wide pressure to build robust release-testing frameworks for living-cell modalities where traditional small-molecule quality paradigms do not directly apply.

CYWC628 is an investigational fibroblast-based therapy intended for patients with diabetic foot ulcers, a chronic wound condition that affects millions of patients globally and has limited effective long-term treatment options. The drug product was manufactured in accordance with FDA current Good Manufacturing Practice requirements and passed all required safety and quality testing prior to release. The Phase 1/2 trial will evaluate safety, tolerability, and preliminary efficacy in DFU patients.

Manufacturing and quality context: Fibroblast-based therapies present distinct process validation and sterility assurance challenges compared with conventional biologics. Cell viability, identity, and potency testing must be integrated into release specifications, and batch consistency across a living-cell matrix demands tightly controlled upstream and downstream processes. The successful release of this first clinical batch signals that FibroBiologics has established a manufacturing baseline sufficient to satisfy FDA's cGMP expectations for Phase 1/2 entry, though process validation at commercial scale remains a longer-term challenge the industry will watch closely.

"With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial," said Pete O'Heeron, Founder and CEO of FibroBiologics. "This milestone allows us to begin the process of generating the data needed to evaluate safety, tolerability, and efficacy in DFUs."

FibroBiologics, headquartered in Houston, holds more than 270 patents issued and pending across its fibroblast platform. The company is listed on Nasdaq under the ticker FBLG. Further information is available at fibrobiologics.com.